Giving the drug abiraterone alongside standard hormone therapy improves the survival of men with high-risk or advanced prostate cancer, according to results from the STAMPEDE trial, published in the New England Journal of Medicine on 3 June 2017. In the “abiraterone comparison” in STAMPEDE, 957 men who were randomised to receive standard of care (hormone therapy with or without radiotherapy) were compared to 960 men who were randomised to receive abiraterone plus prednisolone plus standard of care (hormone therapy with or without radiotherapy). Men in the abiraterone group had four abiraterone tablets and one prednisolone tablet a day. Abiraterone (also known as abiraterone acetate, or Zytiga) is a type of hormone therapy that works in a different way to standard hormone therapy. Abiraterone is currently licensed to treat prostate cancer that has spread and has stopped responding to standard hormone therapy. STAMPEDE tested using it earlier, when men were starting standard hormone th ...

For the purposes of the STAMPEDE trial, a PSA progression value calculator has been created to allow sites to calculate a unique threshold PSA value for biochemical failure for each patient, referred to as the PSA progression value. In the past, research staff have received Progression Letters or contacted the STAMPEDE trial team to obtain this value. However the PSA progression calculator allows research staff to determine the Progression Value themselves, by entering the patient’s PSA results from randomisation to week 24, and printing a copy of the calculation for the patient’s records. We hope with the launch of this calculator it will be easier for you to track a patient’s PSA record and progression status. Additionally we welcome any feedback or suggestions for improvement! For more details see the tools and training section here. ...

We are pleased to inform you of the survival results from the oncology “celecoxib comparisons” have now been published in The Journal of Clinical Oncology. Results from two of the comparisons of the STAMPEDE trial, adding the drug celecoxib (with or without zoledronic acid) to long-term hormone therapy for men with prostate cancer, were published yesterday in the Journal of Clinical Oncology. Overall, the results show no benefit in survival of adding either celecoxib alone, or celecoxib plus zoledronic acid, to long-term hormone therapy, but there are results of significant interest in the sub-group analyses. The results, looking at the entire group of men in the study, come as no surprise, since in 2012, a planned analysis of the trial showed that adding celecoxib, to hormone therapy did not add enough benefit to justify continuing to recruit more patients to these comparisons. The researchers continued to follow-up these men to monitor the long-term effects. These results (with an ...


MRC Clinical Trials Unit at UCL
2nd Floor
90 High Holborn



Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.